2024
conference-abstract
OpenAlex
Jia Li Liu, Nushin Sadeghi, Owen Dan Luo, Jonathan How et autres
Background Acute Myeloid Leukemia (AML) is a common form of leukemia in adults. Gemtuzumab Ozogamicin (GO), an anti-CD33 antibody linked to a chemotherapy molecule, demonstrated improved event-free survival (EFS) and overall survival (OS) in favorable and intermediate risk AML when given with …
ca
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Veronica E. Ramirez, Gizelle Popradi, John M. Storring, Jonathan How
Introduction: Allogeneic hematopoietic stem cell transplant (HCT) is the only curative option for many hematologic malignancies, yet non-relapse mortality (NRM) remains a challenge. Since its development in 2003, the HCT Comorbidity Index (HCT-CI) has been widely adopted to estimate NRM and overall …
ca
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard John Jones et autres
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. …
us, kr, de, jp, gb, il, au
(code pays fourni par la source)
2022
article
OpenAlex
Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano et autres
Background: Myelofibrosis (MF) is a myeloproliferative neoplasm associated with splenomegaly, high symptom burden, bone marrow fibrosis (BMF), and poor prognosis. The Janus kinase inhibitor (JAKi) ruxolitinib is the current standard of care for patients with MF. It improves splenomegaly and disease symptoms …
it, us, es, gb, au, ca
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Safaa Azzouz, Jonathan How
Abstract We present a case of a previously healthy 61-year-old female with a new diagnosis of Giant Cell Arteritis (GCA), initially treated with prednisone. One month later, she receives the diagnosis of Acute Myeloid Leukemia for which she gets a course of …
ca
(code pays fourni par la source)
2018
conference-abstract
OpenAlex
Mahmood Al‐Abri, Jonathan How
Abstract Introduction: Despite a plethora of novel therapies, autologous stem cell transplant (ASCT) continues to offer a progression free survival benefit to multiple myeloma patients. At our institution, standard of care for transplant-eligible patients remains induction with cyclophosphamide, bortezomib, and decadron (CyBorD) …
ca
(code pays fourni par la source)
2015
article
OpenAlex
Min Tang, Nadir Mawji, Samantha Chung, Ryan Brijlal et autres
BACKGROUND: Lung transplant (LT) recipients requiring additional care may be referred to inpatient rehabilitation prior to discharge home. This study seeks to describe discharge destinations following LT, compare the characteristics of patients discharged to different destinations, and identify the predictors of discharge …
ca
(code pays fourni par la source)
Accès ouvert
2015
article
OpenAlex
Jonathan How, Mark David Minden, Brian F. Leber, Eric Xueyu Chen et autres
This phase I trial evaluated two schedules of escalating vorinostat in combination with decitabine every 28 days: (i) sequential or (ii) concurrent. There were three dose-limiting toxicities: grade 3 fatigue and generalized muscle weakness on the sequential schedule (n = 1) and …
ca, us
(code pays fourni par la source)
2014
article
OpenAlex
Moussab Damlaj, Ramila Amre, Phil Wong, Jonathan How
OBJECTIVES: To examine laser microdissection and mass spectrometry (LMD-MS), which has emerged as a new tool to aid in typing amyloid proteins. RESULTS: ALECT-2 is a potential cause of hepatic amyloidosis best detected by LMD-MS. METHODS: One of the more recently reported …
ca
(code pays fourni par la source)
Accès ouvert
2012
article
OpenAlex
Jonathan How, Jenna R. Sykes, Vikas K Gupta, Karen W L Yee et autres
BACKGROUND: In patients with acute myeloid leukemia (AML), testing for fms-like tyrosine kinase-3 (FLT3)-internal tandem duplication (FLT3-ITD) and nucleophosmin-1 (NPM1) mutations can allow for further prognostic subclassification, but less is known about the effects of FLT3-ITD allele burden and presenting white blood …
ca
(code pays fourni par la source)
2012
article
OpenAlex
Jonathan How, Karen W L Yee
INTRODUCTION: Aurora kinases are key regulators of mitosis and inhibition of Aurora kinase activity is a rational therapeutic strategy in the treatment of solid tumors and hematological malignancies. AREAS COVERED: This paper will provide an updated summary of preclinical and clinical experience …
ca
(code pays fourni par la source)
2010
article
OpenAlex
Jonathan How, Margaret R. Warner, Chaim Shustik, Pierre Laneuville
Abstract Abstract 4895 Background: The treatment of primary central nervous system lymphoma (PCNSL) is characterized by high rates of toxicity and intracranial relapse despite initial response. High-dose methotrexate (HD-MTX), with or without cranial irradiation, has become the standard of care; combining this …
ca
(code pays fourni par la source)